June 23

Pharmalittle: Tariffs on China don’t include medicines; 340B purchases are skyrocketing

first_imgPharmalot By Ed Silverman May 14, 2019 Reprints GET STARTED Alex Hogan/STAT STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What is it? Log In | Learn More About the Author Reprints Pharmalittle: Tariffs on China don’t include medicines; 340B purchases are skyrocketing Tags Congressdrug pricinglegalopioidspharmaceuticalspharmalittleSTAT+center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Ed Silverman What’s included? Good morning, everyone, and how are you today? We are doing just fine, thank you, despite persistently soggy and gloomy skies hovering over the Pharmalot campus. As the Morning Mayor used to say: “Every brand new day should be unwrapped like a precious gift.” So while you tug on the ribbon and ponder the possibilities, we will brew another cup of stimulation and proceed with our usual routine of foraging for interesting items. Speaking of which, here are a few tidbits to get you going. Have a smashing day and do keep in touch. …A coalition of pharmaceutical industry critics is accusing the largest drug makers of hiding behind research and development “as an excuse for price-gouging American patients,” STAT writes. And they cite a new study that finds drug makers spent about 22% of their revenues on research and development in 2017 to prove their point. The study, commissioned by the Campaign for Sustainable Rx Pricing, was based largely on analysis of 2017 Security and Exchange Commission filings for the 10 largest U.S.-based drug makers that generate more than half their revenue from medicines. Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. [email protected] @Pharmalot Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTEDlast_img

Tags: , , , , , , , , , , ,
Copyright 2021. All rights reserved.

Posted June 23, 2021 by admin in category "manesxfpy

Leave a Reply

Your email address will not be published. Required fields are marked *